免疫检查点抑制剂在广泛期肺外小细胞癌治疗中的作用
The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Extrapulmonary Small Cell Carcinoma.
作者信息
Aly Ragia, Gupta Sachin, Potdar Rashmika
机构信息
Internal Medicine, Danbury Hospital, Danbury, USA.
Internal Medicine, Reading Hospital, West Reading, USA.
出版信息
Cureus. 2020 Jun 27;12(6):e8862. doi: 10.7759/cureus.8862.
Abstract
Small cell carcinoma is a type of highly aggressive poorly differentiated neuroendocrine tumor that can arise from multiple organs, including but not limited to bronchial tissue, pancreas, gastrointestinal tract, and genitourinary system. The most commonly studied type is small cell lung cancer (SCLC) which carries the worst prognosis among lung cancers. After multiple promising clinical trials, the National Comprehensive Cancer Network has recently added atezolizumab and durvalumab in combination with platinum-based chemotherapy/etoposide to the first-line treatment regimen for extensive-stage SCLC (ES-SCLC). Meanwhile, the recommended treatment for extrapulmonary small cell carcinoma (EPSCC) remains unchanged. In this review, we try to explore the role of immunotherapy in the treatment of EPSCC.
摘要
小细胞癌是一种侵袭性很强的低分化神经内分泌肿瘤，可起源于多个器官，包括但不限于支气管组织、胰腺、胃肠道和泌尿生殖系统。研究最多的类型是小细胞肺癌（SCLC），它在肺癌中预后最差。经过多项前景良好的临床试验后，美国国立综合癌症网络最近将阿特珠单抗和度伐利尤单抗联合铂类化疗/依托泊苷纳入广泛期小细胞肺癌（ES-SCLC）的一线治疗方案。同时，肺外小细胞癌（EPSCC）的推荐治疗方案保持不变。在本综述中，我们试图探讨免疫疗法在EPSCC治疗中的作用。
相似文献
1
The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Extrapulmonary Small Cell Carcinoma.免疫检查点抑制剂在广泛期肺外小细胞癌治疗中的作用
Cureus. 2020 Jun 27;12(6):e8862. doi: 10.7759/cureus.8862.
2
A comparison of the outcomes of pulmonary versus extrapulmonary extensive-stage small cell carcinoma.比较肺性与肺外广泛期小细胞癌的结局。
Intern Med J. 2024 Mar;54(3):414-420. doi: 10.1111/imj.16281. Epub 2023 Nov 27.
3
First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions.广泛期小细胞肺癌的一线免疫检查点抑制剂：临床进展和未来方向。
ESMO Open. 2021 Feb;6(1):100003. doi: 10.1016/j.esmoop.2020.100003. Epub 2021 Jan 13.
4
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.度伐利尤单抗联合铂类依托泊苷与铂类依托泊苷一线治疗广泛期小细胞肺癌（CASPIAN）：一项随机、对照、开放标签、III 期临床试验。
Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4.
5
Immune checkpoint inhibitors: a new landscape for extensive stage small cell lung cancer treatment.免疫检查点抑制剂：广泛期小细胞肺癌治疗的新局面。
Expert Rev Respir Med. 2021 Nov;15(11):1415-1425. doi: 10.1080/17476348.2021.1964362. Epub 2021 Aug 23.
6
Extrapulmonary small cell carcinoma: imaging features with radiologic-pathologic correlation.肺外小细胞癌：影像学特征及影像病理对照
Radiographics. 2015 Jan-Feb;35(1):152-63. doi: 10.1148/rg.351140050.
7
Immunotherapy in Small Cell Lung Cancer.小细胞肺癌的免疫疗法
Cancers (Basel). 2020 Sep 4;12(9):2522. doi: 10.3390/cancers12092522.
8
Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer.免疫检查点抑制剂在小细胞肺癌中的作用。
Am J Ther. 2018 May/Jun;25(3):e349-e356. doi: 10.1097/MJT.0000000000000686.
9
Immunotherapy for extensive stage small cell lung cancer.广泛期小细胞肺癌的免疫治疗
J Thorac Dis. 2020 Oct;12(10):6212-6224. doi: 10.21037/jtd.2020.01.37.
10
What is the role of radiotherapy for extensive-stage small cell lung cancer in the immunotherapy era?在免疫治疗时代，放疗对于广泛期小细胞肺癌的作用是什么？
Transl Lung Cancer Res. 2019 Sep;8(Suppl 2):S153-S162. doi: 10.21037/tlcr.2019.05.01.
引用本文的文献
1
Patterns of Immunoreactivity with TTF-1 Antibodies 8G7G3/1 and SPT24 Suggest Distinct Immunoprofiles Between Most Pulmonary and Nonpulmonary Small Cell Carcinomas.TTF-1 抗体 8G7G3/1 和 SPT24 的免疫反应模式表明大多数肺和非肺小细胞癌之间存在不同的免疫表型。
Int J Surg Pathol. 2024 Apr;32(2):230-238. doi: 10.1177/10668969231171940. Epub 2023 May 11.
2
Extrapulmonary Small Cell Carcinoma Presenting as an Orbital Mass: A Case Report.表现为眼眶肿物的肺外小细胞癌：一例报告
Cureus. 2022 Jun 16;14(6):e26012. doi: 10.7759/cureus.26012. eCollection 2022 Jun.
3
Clinical Characteristics and Prognosis of Small Cell Carcinoma in the Nasopharynx: A Population-Based Study.基于人群的鼻咽癌小细胞癌临床特征及预后研究
Cancer Control. 2022 Jan-Dec;29:10732748221087075. doi: 10.1177/10732748221087075.
本文引用的文献
1
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence.根据美国国立综合癌症网络（NCCN）指南及证据水平对美国食品药品监督管理局（FDA）批准的免疫检查点抑制剂适应症的综述。
Cancers (Basel). 2020 Mar 20;12(3):738. doi: 10.3390/cancers12030738.
2
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.度伐利尤单抗联合铂类依托泊苷与铂类依托泊苷一线治疗广泛期小细胞肺癌（CASPIAN）：一项随机、对照、开放标签、III 期临床试验。
Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4.
3
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.KEYNOTE-590：帕博利珠单抗联合或不联合化疗一线治疗晚期食管癌的 III 期研究。
Future Oncol. 2019 Apr;15(10):1057-1066. doi: 10.2217/fon-2018-0609. Epub 2019 Feb 8.
4
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032.三线纳武利尤单抗单药治疗复发性小细胞肺癌：CheckMate 032。
J Thorac Oncol. 2019 Feb;14(2):237-244. doi: 10.1016/j.jtho.2018.10.003. Epub 2018 Oct 10.
5
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.阿替利珠单抗联合化疗一线治疗广泛期小细胞肺癌。
N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25.
6
Role of Immune Checkpoint Inhibitors in Advanced or Recurrent Endometrial Cancer.免疫检查点抑制剂在晚期或复发性子宫内膜癌中的作用
Cureus. 2018 Apr 23;10(4):e2521. doi: 10.7759/cureus.2521.
7
Immunohistochemical expression and prognostic value of PD-L1 in Extrapulmonary small cell carcinoma: a single institution experience.免疫组织化学表达及 PD-L1 在外周型小细胞肺癌中的预后价值：单中心经验
J Immunother Cancer. 2018 May 29;6(1):42. doi: 10.1186/s40425-018-0359-1.
8
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.帕博利珠单抗单药治疗既往治疗的晚期胃和胃食管结合部癌患者的安全性和疗效：Ⅱ期 KEYNOTE-059 临床试验。
JAMA Oncol. 2018 May 10;4(5):e180013. doi: 10.1001/jamaoncol.2018.0013.
9
De-novo and acquired resistance to immune checkpoint targeting.免疫检查点靶向治疗的获得性和新生耐药性。
Lancet Oncol. 2017 Dec;18(12):e731-e741. doi: 10.1016/S1470-2045(17)30607-1.
10
Dramatic Response of a Metastatic Primary Small-Cell Carcinoma of the Pancreas to a Trial of Immunotherapy with Nivolumab: A Case Report.胰腺原发性小细胞癌转移灶对纳武单抗免疫治疗试验的显著反应：一例报告
Case Rep Oncol. 2017 Aug 9;10(2):720-725. doi: 10.1159/000479315. eCollection 2017 May-Aug.
Zotero 插件